Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.55B 11.03B 10.25B 9.41B 17.68B 1,209B 17.95B 122B 47.57B 594B 47.13B 46.11B 2,055B P/E 2026 *
-74.4x
P/E 2027 * 63.8x
Enterprise Value 12.04B 10.57B 9.83B 9.02B 16.95B 1,159B 17.22B 117B 45.62B 570B 45.19B 44.22B 1,971B EV / Sales 2026 *
8.03x
EV / Sales 2027 * 5.27x
Free-Float
94.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.21%
1 week-1.62%
Current month+1.41%
1 month+6.82%
3 months+6.27%
6 months+13.33%
Current year-6.50%
1 week 526.6
Extreme 526.605
555.05
1 month 505.63
Extreme 505.63
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/6/26 Free

Director

1,220 0.0053%
17/6/26
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-1.62%+82.01%+164.74% 12.55B
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -0.92%+0.99%+44.76%+170.33% 25.27B
Weighted average by Cap. -0.82%+1.91%+43.21%+137.13%

Financials

2026 *2027 *
Net sales 1.5B 1.32B 1.22B 1.12B 2.11B 144B 2.14B 14.53B 5.68B 70.94B 5.63B 5.5B 245B 2.18B 1.91B 1.78B 1.63B 3.07B 210B 3.12B 21.14B 8.26B 103B 8.18B 8.01B 357B
Net income -210M -184M -171M -157M -295M -20.19B -300M -2.03B -794M -9.92B -787M -770M -34.31B 264M 232M 216M 198M 372M 25.41B 377M 2.56B 1B 12.49B 991M 969M 43.19B
Net Debt -515M -452M -421M -386M -725M -49.61B -737M -5B -1.95B -24.39B -1.93B -1.89B -84.33B -1.08B -945M -879M -806M -1.52B -104B -1.54B -10.44B -4.08B -50.94B -4.04B -3.95B -176B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
24/07/26 USD 544.51 +0.21% 147,390
23/07/26 USD 543.35 +1.06% 160,514
22/07/26 USD 537.65 -1.67% 310,899
21/07/26 USD 546.79 +2.07% 222,279
20/07/26 USD 535.69 -3.21% 223,809
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
544.51USD
Average target price
679.64USD
Spread / Average Target
+24.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock